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A large multicenter analysis of CTGF -945 promoter polymorphism does not 
confirm association with Systemic Sclerosis susceptibility or phenotype. 
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ABSTRACT 
Objective: In this work we conducted a replication study to investigate whether the -
945 CTGF genetic variant is associated with SSc susceptibility or specific SSc 
phenotype.  
Methods: The study population comprised of 1180 SSc patients and 1784 healthy 
controls from seven independent case-control sets of European ancestry (Spanish, 
French, Dutch, German, British, Swedish and North American). The –945 CTGF 
genetic variant was genotyped using a Taqman 5  ´allelic discrimination assay.  
Results: First we conducted an independent association study that revealed in all case-
control cohorts under study no association of the CTGF -945 polymorphism with SSc 
susceptibility. These findings were confirmed by a meta-analysis that reached a pooled 
OR of 1.12 (95 % CI 0.99-1.25, P=0.06). In addition, the possible contribution of the -
945 CTGF genetic variant to SSc phenotype was investigated. However, stratification 
according to SSc subtypes (limited or diffuse), selective autoantibodies 
(antitopoisomerase I or anti-centromere) or pulmonary involvement reached no 
statistically significant skewing.  
Conclusion: Our results do not confirm previous findings and suggest that the CTGF –
945 promoter polymorphism does not play a major role in SSc susceptibility or clinical 
phenotype.  
 
 
KEY WORDS: Systemic slcerosis, connective tissue growth factor, association study, 
polymorphism. 
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INTRODUCTION 
 
Systemic sclerosis (SSc) is an autoimmune disorder characterized by excessive fibrosis, 
vascular abnormalities and immune system dysfunction that can affect several organs or 
tissues (mainly skin, lungs and kidneys).[1] 
The genetic component of SSc is supported by familial aggregation and ethnic 
influences, however individual genetic markers or genes have generally not shown 
reproducible association with SSc susceptibility so far. Most of the candidate gene 
association studies conducted in SSc are limited by insufficient statistical power due to 
the small sample sizes analysed and by the lack of replication in independent 
populations.[1] 
Recently, the connective tissue growth factor (CTGF) gene has been suggested as a 
novel genetic marker for SSc susceptibility. A putative functional single nucleotide 
polymorphism (SNP) located in the promoter region of CTGF gene (rs6918698; -945 
C/G) was significantly associated with SSc susceptibility and with certain clinical 
hallmarks of this condition in a British population.[2] However, these findings were not 
replicated in a North American case-control set in which the CTGF -945 genetic variant 
showed no association with SSc susceptibility or phenotype.[3]  
In view of these controversial results and in order to better understand the role of the 
CTGF gene in SSc pathogenesis, we designed a large replication study including seven 
independent case-control sets of Caucasian ancestry to investigate whether the -945 
CTGF genetic variant is implicated in SSc susceptibility or clinical manifestations.  
 
MATERIAL AND METHODS 
 
Patients 
The study population consisted of a total of 1180 SSc patients and 1784 healthy controls 
from seven independent case-control sets of European ancestry (Spanish: 317 SSc and 
369 controls; French: 98 SSc and 146 controls, Dutch: 140 SSc and 267 controls; 
German: 251 SSc and 276 controls; British: 145 SSc and 351 controls and Swedish: 119 
SSc and 277 controls; North American: 120 SSc and 98 healthy controls). All the 
patients fulfilled the 1980 American College of Rheumatology (ACR) classification 
criteria for SSc.[4]  
The control population consisted in unrelated healthy individuals matched by age, sex 
and ethnicity with the SSc patients groups.  
The study was approved by local ethical committees from all the participating centers. 
Both patients and controls were included in the study after written informed consent. 
SSc patients were classified as having limited or diffuse SSc.[5, 6] The seven patients 
groups were comparable in terms of age, gender and disease duration. Data regarding 
selective autoantibodies status was not available in all SSc patients: 983 patients were 
assessed for the presence of anti-topoisomerase I (anti-Scl-70) and 902 for anti-
centromere antibodies (ACA). Involvement of the lungs was assessed in 750 SSc 
patients according to the international guidelines.[7] The presence of pulmonary fibrosis 
was investigated by a computed tomography scan. Restrictive syndrome and diffusion 
capacity of the lungs was defined as a forced vital capacity (FVC) < 75% of the 
predicted value and a diffusion capacity of the lung for carbon monoxide (DLCO) of 
less than 75% of predicted. 
CTGF -945 genotyping. 
 on 22 July 2009 ard.bmj.comDownloaded from 
 4
DNA samples from patients and controls were genotyped for the CTGF -945 
polymorphism using a Custom-Taqman-SNP-Genotyping-Assay (Applied Biosystems, 
Foster City, CA, USA) (primers and probes sequences are available under request). 
The PCR reaction was performed as follows: 92ºC-10 min, 40 cycles of 92ºC-15 sec 
and 60 ºC-1:00 min. Post-PCR, the genotype of each sample was automatically 
attributed in the ABI Prism 7900 Sequence Detection System using the SDS 2.3 
software for allele discrimination (Applied Biosystems, Foster City, CA, USA).  
Statistical analysis 
We tested Hardy-Weinberg equilibrium (HWE) by using the program FINETI 
(http://ihg.gsf.de/cgi-bin/hw/hwa2.pl). Significance was calculated by 2x2 contingency 
tables and Fisher’s exact test, to obtain p values, odds ratios (OR) and 95% confidence 
intervals (CI) by using Statcalc software (Epi Info 2002; Centers for Disease Control 
and Prevention, Atlanta, GA, USA). P values below 0.05 were considered as 
statistically significant. The analysis of the combined data from all populations was 
performed using the Stats Direct software. Homogeneity of OR among cohorts was 
calculated using Breslow-Day and Woolf Q methods and the calculation of the pooled 
OR was performed under a fixed-effects model (Mantel-Haenszel meta-analysis) or 
random effects (DerSimonian-Laird) when necessary. 
The estimation of the power of the study was performed using the Quanto v 0.5 
software (Department of Preventive Medicine University of Southern California, 
California, USA.) 
 
RESULTS 
 
The CTGF -945 genetic variant was analysed in seven populations from Spain, France, 
The Netherlands, Germany, United Kingdom, Sweden and North America. In all of 
them, both SSc patients and controls group were found to be in Hardy-Weinberg 
equilibrium for CTGF -945 genotypes.  
The individual analysis revealed the same trend in all populations showing no 
association of the CTGF -945 polymorphism with SSc susceptibility considering either 
allelic or genotypic frequencies (Table 1).  
To further investigate the possible role of the CTGF -945 polymorphism in SSc 
susceptibility, we conducted a combined analysis including the seven case-control 
series. The estimation of the homogeneity between populations revealed that all of them 
could be combined. Therefore, we performed a meta-analysis under fixed-effects using 
the Mantel-Haenszel test that reached a p value of 0.06 and pooled OR of 1.12 for the C 
allele (95 % CI 0.99-1.25). Thus, we confirmed the lack of association of the CTGF -
945 polymorphism with SSc susceptibility observed in the independent analysis. 
The possible contribution of  -945 CTGF genetic variant to SSc phenotype was also 
investigated. After stratification of SSc patients according to skin involvement, presence 
of autoantibodies or lung involvement, no statistically significant skewing was observed 
(data not shown).  
 
DISCUSSION 
 
Association studies of functional candidate genes represent one of the most powerful 
and direct approaches to investigate the genetic component of human complex 
diseases.[8] However, to validate genetic associations the replication of results in 
independent. populations is mandatory. Only genetic associations consistently 
reproducible among populations strengthen the confidence in association studies.[9] 
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In this line, a recent report showed association of the CTGF -945 promoter 
polymorphism with SSc susceptibility in a British population, whereas the same SNP 
tested in a North American population did not reach any significant association.[2] Due 
to the controversial results obtained in these studies the role of CTGF as a genetic 
marker for SSc was unclear. 
In order to support additional information that could help to clarify the possible 
contribution of CTGF gene in SSc susceptibility, we analysed the -945 CTGF promoter 
polymorphism in a large cohort of SSc patients originating from seven independent 
replication cohorts. After independent association studies and a meta-analysis, we did 
not observe a significant association of CTGF -945 genetic variant with SSc 
susceptibility or clinical manifestations.  
The lack of association observed in our study is unlikely due to low statistical power 
since the total sample size analyzed (1180 SSc patients and 1784 controls) represents a 
power of 99% to detect an association with a genetic marker assuming OR from 1.5 to 
2.2 (similar to that observed in the Fonseca et al study), at the 5 % significance level. 
Furthermore, the replication of the results in seven independent cohorts, supports the 
notion that our results are unlikely due to the type II error. The discrpancies between 
our findings and those by Fonseca et al. could be due to differences in the distribution of 
CTGF -945 genotypes. The frequency for the GG genotype observed in our case-control 
sets range between 24.4% and 33.7%, which is also similar to the frequency of the GG 
genotype in the USA cohort.[3] However, this gentoype showed a lower frequency in 
SSc patients from the initial British study (19.8%).[2] Although these differences could 
be due to different genetic background, this seems not to be the case since we included 
in our study a British population that showed a frequency of 27.6 % for the GG 
genotype. Thus, our findings confirm those obtained by Gourh P et al that failed to 
replicate the association of -945 CTGF polymorphism with SSc susceptibility or its 
autoantibody or clinical subgroups.[3]  
The excessive scarring process that leads to the most important clinical complications in 
SSc is still poorly understood. A complex interaction among pro-fibrotic proteins 
including CTGF, and driven by transforming growth factor betha (TGFβ), is thought to 
mediate the fibrogenic response. The expression of CTGF is induced by TGFβ and 
endothelin 1 (ET-1).[10-12] Therefore it could be speculated that the increased 
expression of CTGF observed in SSc patients [13] might be due to the induction of 
potent pro-fibrogenic mediators upstream of CTGF, rather than to genetic variants that 
could alter the activity of  the CTGF promoter.  
Further studies are necessary to understand the exact role of CTGF in the complex 
cascade that lead to the exacerbated scaring present in SSc and to better characterize 
which genetic elements regulate CTGF expression.  
In summary, through a large replication study we could not confirm a major role of the 
–945 CTGF promoter polymorphism in SSc susceptibility or phenotype expression. Our 
results, together with previous findings strongly suggest that the CTGF -945 
polymorphisms does not seem to be a determinant genetic marker for SSc.  
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Table 1. Genotype and allele frequencies of CTGF -945 promoter polymorphism in the six case-control sets analysed. 
 
Population  CC CG GG Allele C Allele G P value allele OR (95%CI) 
Spanish Cases (317) 82 (25.9) 146 (46.1) 89 (28.1) 310 (48.9) 324 (51.1) 0.75 1.03 (0.8-1.3) 
 Controls (369) 96 (26.0) 175 (47.4) 98 (26.6) 367 (49.7) 371 (50.3)   
French Cases (98) 26 (26.5) 46 (46.9) 26 (26.5) 98 (50.0) 98 (50.0) 0.71 1.07 (0.7-1.5) 
 Controls (146) 36 (24.7) 69 (47.3) 41 (28.1) 141 (48.3) 151 (51.7)   
Dutch  Cases (140) 32 (22.9) 71 (50.7) 37 (26.4) 135 (48.2) 145 (51.8) 0.63 1.07 (0.8-1.4) 
 Controls (267) 56 (21.0) 136 (50.9) 75 (28.1) 248 (46.6) 286 (53.6)   
Swedish Cases (119) 36 (30.3) 54 (45.4) 29 (24.4) 126 (52.9) 112 (47.1) 0.29 1.17 (0.9-1.6) 
 Controls (277) 74 (26.7) 123 (44.4) 80 (28.9) 271 (48.9) 283 (51.1)   
German Cases (241) 57 (23.7) 112 (46.5) 72 (29.9) 226 (46.9) 256 (53.1) 0.14 1.20 (0.9-1.5) 
 Controls (276) 51 (18.5) 132 (47.8) 93 (33.7) 234 (42.4) 318 (57.6)   
British Cases (145) 39 (26.9) 66 (45.5) 40 (27.6) 144 (49.7) 146 (50.3) 0.11 1.25 (0.9-1.6) 
 Controls (351) 62 (17.7) 186 (53.0) 103 (29.3) 310 (44.2) 392 (55.8)   
North American Cases (120) 31 (25.8) 55 (45.8) 34 (28.3) 117 (48.8) 123 (51.3) 0.36 1.19 (0.8-1.7) 
 Controls (98) 21 (21.4) 45 (45.9) 32 (32.7) 87 (44.4) 109 (55.6)   
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